GeSRU-Academics, Frankfurt, Germany; Department of Urology and Pediatric Urology, University Medical Center, Mainz, Germany.
GeSRU-Academics, Frankfurt, Germany; Department of Urology and Pediatric Urology, University Medical Center, Mainz, Germany.
Clin Genitourin Cancer. 2021 Apr;19(2):162-166.e1. doi: 10.1016/j.clgc.2020.12.004. Epub 2021 Jan 7.
Overdiagnosis and overtherapy in prostate cancer (PCa) treatment should be avoided, which has led to an awareness of the need to decrease treatment in cases of low-risk PCa with radical prostatectomy (RP). Simultaneously, prostate-specific antigen testing has become less popular in the last few years, which has resulted in higher cancer grade and stage at diagnosis. We evaluated stage and grade migration in the disease of patients treated with RP in a large German cohort.
Overall, 4842 patients undergoing RP between 2000 and 2019 were included. Age, prostate-specific antigen level, biopsy, and pathologic Gleason score as well as clinical and pathologic stage were collected. D'Amico risk groups and Gleason score were evaluated over different time points.
We detected a significant grade migration toward higher grade. The proportion of biopsy Gleason sum ≤ 6 dropped from 45.8% to 20.6% between ≤ 2010 and 2017-2019. Further, the proportion of patients with low D'Amico risk scores also decreased by almost 50% (20.8% vs 12.2%). Finally, the proportion of non-organ-confined PCa increased over time, and the proportion of postoperative Gleason sum ≤ 6 decreased from 20% to 10% over time.
Taken together, data indicate a significant preoperative grade and stage migration toward disease of higher grade in RP-treated PCa. Between the years 2000 and 2019, the proportion of biopsy Gleason sum ≤ 6 and the proportions of D'Amico low risk disease decreased by approximately 50% (respectively, 45% to 20% and 20.8% to 12.2%). This might indicate better patient selection for RP, but might also be a telltale sign of the rising mortality and morbidity of PCa.
在前列腺癌(PCa)的治疗中,应避免过度诊断和过度治疗,这使得人们认识到需要降低低危 PCa 根治性前列腺切除术(RP)的治疗。同时,前列腺特异性抗原检测在过去几年中变得不那么流行,导致诊断时癌症分级和分期更高。我们评估了在德国大型队列中接受 RP 治疗的患者的疾病中分期和分级的迁移。
共纳入 2000 年至 2019 年间接受 RP 的 4842 例患者。收集年龄、前列腺特异性抗原水平、活检和病理 Gleason 评分以及临床和病理分期。评估不同时间点的 D'Amico 风险组和 Gleason 评分。
我们发现分级向更高分级显著迁移。活检 Gleason 总和≤6 的比例从 2010 年之前的 45.8%降至 2017-2019 年的 20.6%。此外,低 D'Amico 风险评分的患者比例也下降了近 50%(20.8%降至 12.2%)。最后,非器官受限 PCa 的比例随时间增加,术后 Gleason 总和≤6 的比例随时间从 20%降至 10%。
总之,数据表明 RP 治疗的 PCa 患者术前分级和分期向更高分级显著迁移。2000 年至 2019 年间,活检 Gleason 总和≤6 的比例和 D'Amico 低危疾病的比例分别下降了约 50%(分别为 45%降至 20%和 20.8%降至 12.2%)。这可能表明对 RP 的患者选择更好,但也可能是 PCa 死亡率和发病率上升的一个迹象。